Product comprising a transduction inhibitor of heterotrimeric g protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer

A composition for treating cancer comprising an antitumorally effective amount of a product comprising:

• a pharmaceutically acceptable carrier,
• at least one transduction inhibitor of heterotrimeric G protein signals selected from the group consisting of 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methylphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine:
• 7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
• mixtures thereof;
• and pharmaceutically acceptable salts thereof;
• and
• at least one other anti-cancer agent selected from the group consisting of 1-(2-(1-((4-cyano)phenylmethyl)imidazol-4-yl)1-oxoethyl-2,5-dihydro-4-(2-methoxyphenyl)imidazo[1,2c][1,4]benzodiazetpine, 4-(2-bromophenyl)-1-(2-(1-((4-cyano-3-methoxy)phenylmethyl)-imidazo-5-yl-1-oxoethyl)-1,2-dihydro-8-fluoro-imidazo[1,2a][1,4]-benzodiazepine, (±) 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-amino-(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)quinolinone;
• taxol;
• gemcitabine;
• mixtures thereof;
• and pharmaceutically acceptable salts thereof;
• wherein the composition is administered simultaneously, separately or spread over a period of time.